Bayer begins $240m AI drug discovery project with Exscientia
10-01-2020
blackjack3d / iStockphoto.com
GSK has entered into a strategic drug discovery collaboration with an artificial intelligence-driven (AI) drug discovery company, Exscientia.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
GSK, Exscientia, collaboration, drug discovery, artificial intelligence, small molecules
